跳至主要内容
临床试验/NCT07674719
NCT07674719尚未招募不适用

The Effect of Intraoperative Remimazolam Administration on the Incidence of Postoperative Acute Kidney Injury After Hepatobiliary and Pancreatic Surgery : a Prospective Randomized Controlled Trial

Seoul National University Bundang Hospital1 个研究点 分布在 1 个国家目标入组 78 人开始时间: 2026年6月26日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
尚未招募
入组人数
78
试验地点
1
主要终点
Acute kidney injury

研究概览

简要总结

We hypothesized that in patients undergoing elective hepatobiliary-pancreatic surgery, the group in which anesthesia is induced and maintained with remimazolam during surgery would maintain hemodynamic stability and reduce the incidence of postoperative acute kidney injury compared to propofol. The purpose is to provide practical evidence for perioperative management differentiated from other surgeries for hepatobiliary-pancreatic surgery patients for whom intraoperative fluid therapy is restricted.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
19 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Ages 19 or older and under 85
  • Patients scheduled to undergo elective hepatopancreatic surgery under general anesthesia
  • American Society of Anesthesiologists (ASA) physical grade 1-3
  • Those who voluntarily consented to a written informed consent form prior to participation in the study

排除标准

  • Patients with hypersensitivity to other benzodiazepine drugs, including remimazolam, and to the components of this drug (e.g., patients with severe hypersensitivity to dextran 40)
  • Patients with hypersensitivity to propofol
  • Patients with underlying conditions: liver, neurological disorders, or acute narrow-angle glaucoma
  • Patients with severe or acute respiratory failure
  • Patients in shock or a coma
  • Patients taking TCA antidepressants
  • Patients with preoperative chronic kidney disease

研究组 & 干预措施

Remimazolam

Experimental

干预措施: Remimazolam (Byfavo) (Drug)

Propofol

Active Comparator

干预措施: propofol (Drug)

结局指标

主要结局

Acute kidney injury

时间窗: preop, postop day 0, 1, 3, 5

serum creatinine

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Park InSun

Assistant Professor

Seoul National University Bundang Hospital

研究点 (1)

Loading locations...

相似试验